Ellington Management Group’s TG Therapeutics TGTX Stock Holding History

Ellington Management Group’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-21,600	Closed	-$307K	–	846
2018 Q1	$307K	Sell	21,600 -3,100	-13%	-$39.6K	0.02%	585
2017 Q4	$203K	Buy	+24,700	New	+$216K	0.03%	486
2017 Q1	–	Sell	-29,500	Closed	-$137K	–	870
2016 Q4	$137K	Buy	+29,500	New	+$173K	0.02%	483
2016 Q3	–	Sell	-14,300	Closed	-$87K	–	701
2016 Q2	$87K	Sell	14,300 -5,100	-26%	-$41.5K	0.12%	222
2016 Q1	$165K	Buy	19,400 +9,051	+87%	+$79.2K	0.07%	432
2015 Q4	$123K	Buy	+10,349	New	+$131K	0.04%	530
2015 Q3	–	Sell	-33,200	Closed	-$551K	–	895
2015 Q2	$551K	Buy	+33,200	New	+$526K	0.13%	216

Other funds holding TGTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ellington Management Group's TGTX Position: Q2 2018 in Review

Ellington Management Group sold out of TG Therapeutics (TGTX) in Q2 2018, closing a stake of 21,600 shares — an estimated $307K sold.

Ellington Management Group first reported a position in TGTX in Q2 2015 and held it in 7 quarters. The position peaked at $551K in Q2 2015. 132 funds tracked by Wall St. Rank hold TGTX as of Q2 2018.

Ellington Management Group reported no remaining TG Therapeutics position as of Q2 2018 after selling out during the quarter.
Ellington Management Group sold 21,600 TG Therapeutics shares in Q2 2018, an estimated $307K.
Ellington Management Group first reported a position in TG Therapeutics in Q2 2015 and held it in 7 quarters.
Ellington Management Group's TG Therapeutics position peaked at $551K in Q2 2015.
132 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2018.

Based on Ellington Management Group's 13F filing for Q2 2018, filed 14 Aug 2018.